These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31187162)

  • 1. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
    Goncalves I; Burbury K; Michael M; Iravani A; Ravi Kumar AS; Akhurst T; Tiong IS; Blombery P; Hofman MS; Westerman D; Hicks RJ; Kong G
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1902-1910. PubMed ID: 31187162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
    Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
    Thang SP; Lung MS; Kong G; Hofman MS; Callahan J; Michael M; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):262-277. PubMed ID: 28894897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of "Sandwich" chemo-PRRT: a novel treatment strategy for metastatic neuroendocrine tumors with both FDG- and SSTR-avid aggressive disease.
    Parghane RV; Ostwal V; Ramaswamy A; Bhandare M; Chaudhari V; Talole S; Shrikhande SV; Basu S
    Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):913-923. PubMed ID: 32876706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
    Parghane RV; Talole S; Prabhash K; Basu S
    Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
    Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
    Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage peptide receptor radionuclide therapy with [
    van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with
    Alipour R; Jackson P; Bressel M; Hogg A; Callahan J; Hicks RJ; Kong G
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2997-3010. PubMed ID: 37184682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival.
    Chantadisai M; Kulkarni HR; Baum RP
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1390-1398. PubMed ID: 33247328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of receptor radionuclide therapy with
    Nicolini S; Severi S; Ianniello A; Sansovini M; Ambrosetti A; Bongiovanni A; Scarpi E; Di Mauro F; Rossi A; Matteucci F; Paganelli G
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):923-930. PubMed ID: 29387927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
    Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review.
    Chan DS; Kanagaratnam AL; Pavlakis N; Chan DL
    J Neuroendocrinol; 2023 Nov; ():e13355. PubMed ID: 37987535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response.
    Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S
    Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours.
    Almeamar H; Cullen L; Murphy DJ; Crowley RK; Toumpanakis C; Welin S; O'Shea D; O'Toole D
    J Neuroendocrinol; 2022 Jun; 34(6):e13138. PubMed ID: 35485450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours.
    Kashyap R; Hofman MS; Michael M; Kong G; Akhurst T; Eu P; Zannino D; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):176-85. PubMed ID: 25209134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment and Long-Term Safety Outcomes of Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumours: An Asian Experience.
    Tham WY; Huang HL; Tai DWM; Allen JC; Hwang JSG; Loh LM; Goh BKP; Ong SYK; Kek PC; Tan DMY; Ng DCE; Loke KSH
    Neuroendocrinology; 2024; 114(9):840-847. PubMed ID: 38531329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.